Torrent Pharma unveils generic version of Keveyis tablets in US
Dichlorphenamide Tablets are indicated for the treatment of primary hyperkalemic periodic paralysis and related variants.
Basking Ridge: Torrent Pharma has begun shipping the generic version of Xeris's Keveyis (dichlorphenamide), 50mg tablets, following final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application.
Torrent is distributing the product through select specialty pharmacies beginning this month.
Dichlorphenamide Tablets are indicated for the treatment of primary hyperkalemic periodic paralysis and related variants.
Primary periodic paralysis (PPP) is a rare condition that causes sudden episodes that affect the muscles, resulting in extreme muscle weakness or temporary paralysis – most often the inability to move the muscles of the arms and legs.
Torrent Pharma is an Indian multinational pharmaceutical company headquartered in Ahmedabad, India. The company specializes in the therapeutic segments of cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), and women healthcare (WHC). The Company also has a significant presence in diabetology, pain management, gynaecology, oncology, and anti-infective segments. The Company also has a significant presence in diabetology, pain management, gynaecology, oncology, and anti-infective segments. Torrent Pharma has a widespread global presence in over 40 countries.
Read also: Torrent Pharma Shelcal 500 enters market as OTC calcium supplement brand
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.